Clinical efficacy of Ranibizumab in the treatment of wet age-related macular degeneration

Ling-Jun Wei; Hai-Tao Zheng

doi:10.3980/j.issn.1672-5123.2017.12.35

Guoji Yanke Zazhi (Dec 2017)

Clinical efficacy of Ranibizumab in the treatment of wet age-related macular degeneration

Ling-Jun Wei,
Hai-Tao Zheng

Affiliations

Ling-Jun Wei: Department of Ophthalmology,Central Hospital of Zhoukou, Zhoukou 466000, Henan Province, China
Hai-Tao Zheng: Department of Ophthalmology,Central Hospital of Zhoukou, Zhoukou 466000, Henan Province, China

DOI: https://doi.org/10.3980/j.issn.1672-5123.2017.12.35
Journal volume & issue: Vol. 17, no. 12
pp. 2328 – 2330

Abstract

Read online

AIM:To analyze the clinical efficacy of Ranibizumab in the treatment of wet age-related macular degeneration(ARMD).METHODS: Clinical data of patients with wet age-related macular degeneration received treatment of ranibizumab at our hospital from 2015 to 2017 were analyzed. At 1mo after treatment, the clinical efficacy, ocular hemodynamics and ocular inflammation were evaluated. RESULTS: A total of 41 patients were analyzed. After treatment, patients got significantly increased in LogMAR(0.651±0.067 vs 0.321±0.049; t=25.460, Pvs 452.9±69.8μm; t=15.740, Pvs 16.1±3.5ng/L; t=3.563, Pvs 13.8±2.5ng/L; t=3.467, PP>0.05). CONCLUSION: In the treatment of wet age-related macular degeneration, the ranibizumab shows a good therapeutic effect without serious adverse drug reactions.

Published in Guoji Yanke Zazhi

ISSN: 1672-5123 (Print)
Publisher: Press of International Journal of Ophthalmology (IJO PRESS)
Country of publisher: China
LCC subjects: Medicine: Ophthalmology
Website: http://ies.ijo.cn/

About the journal

Abstract

Keywords